Search results for "030211 gastroenterology & hepatology"

showing 10 items of 1275 documents

Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder.

2017

International audience; BACKGROUND & AIM:Several types of unexplained extra-hepatic manifestations, including haematological disorders, have been reported in the context of hepatitis E virus (HEV) infection. However, the underlying mechanism(s) of these manifestations are unknown. We provide evidence that HEV has an extra-hepatic endothelial tropism that can engage cutaneous T cells towards clonality.METHODS:A patient with a CD30(+) cutaneous T cell lymphoproliferative disorder (T-LPD) and biopsy-proven chronic HEV infection received three rounds of oral ribavirin treatment, administered either without or with interferon, and eventually achieved a sustained virologic response (SVR). Patholo…

0301 basic medicineMaleSkin NeoplasmsLymphomaLymphomatoid papulosisT cellLymphoproliferative disordersKi-1 Antigen[SDV.CAN]Life Sciences [q-bio]/CancerExtra-hepatic manifestationNHL[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciencesInterleukin 210302 clinical medicineEndothelial cellInterferonHepatitis E virusMedicineHumansCD30-positive cutaneous T cell lymphoproliferative disorderTropismHepatologybusiness.industryvirus diseasesMiddle Agedmedicine.diseaseVirologyHepatitis ELymphoma T-Cell CutaneousViral Tropism030104 developmental biologymedicine.anatomical_structureHEVImmunologyTissue tropism030211 gastroenterology & hepatologybusinessMemory T cellCD8medicine.drugJournal of hepatology
researchProduct

Angiotensin II type II receptors and colonic dysmotility in 2,4-dinitrofluorobenzenesulfonic acid-induced colitis in rats

2016

Background: Angiotensin II (Ang II), the main peptide of the renin-angiotensin system (RAS), has been suggested to be involved in inflammatory bowel diseases. Since RAS has emerged as gut motility regulator, and dysmotility is associated with intestinal inflammation, our objective was to investigate in rat 2,4-dinitrobenzenesulfonic acid (DNBS)-induced colitis the functionality of RAS and its contribution to colonic motor alterations. Methods: The effects of Ang II on the longitudinal colonic muscular contractility of control and DNBS-treated rats were characterized in vitro. Transcripts encoding for Ang II receptors were investigated by RT-PCR. Key Results: Inflamed preparations showed a l…

0301 basic medicineMalemedicine.medical_specialtyAngiotensin receptormedicine.drug_classColonPhysiologyInflammationAT2 receptorReceptor Angiotensin Type 2Bowel inflammationEndocrine and Autonomic SystemContractilityRenin-Angiotensin System03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsRats WistarReceptorAngiotensin II receptor type 1Endocrine and Autonomic SystemsChemistryAT1 receptorAngiotensin IIMuscle contractilityGastroenterologyMuscle SmoothNitric oxideReceptor antagonistColitisAngiotensin II030104 developmental biologyEndocrinologyLosartancardiovascular system030211 gastroenterology & hepatologyDinitrofluorobenzenemedicine.symptomGastrointestinal Motilityhormones hormone substitutes and hormone antagonistsmedicine.drugMuscle Contraction
researchProduct

Elevated Fatty Liver Index as a Risk Factor for All‐Cause Mortality in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients (ANRS CO13 …

2020

International audience; Background and aims: Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic complications and liver-related events, which are both associated with hepatic steatosis and its progressive form, nonalcoholic steatohepatitis, a known risk factor for mortality. The fatty liver index (FLI), a noninvasive steatosis biomarker, has recently drawn attention for its clinical prognostic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated. Using a Cox proportional hazards model for mortality from all causes, with data from the French National Agency for Research on A…

0301 basic medicineMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatment[SDV]Life Sciences [q-bio]HIV InfectionsLiver transplantationmedicine.disease_causeGastroenterologyAntiviral AgentsCohort Studies03 medical and health sciences0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicineCause of DeathmedicineHumansRisk factorComputingMilieux_MISCELLANEOUSHepatologybusiness.industryCoinfectionHazard ratioFatty liverHepatitis C ChronicMiddle Agedmedicine.disease3. Good healthFatty Liver[SDV] Life Sciences [q-bio]030104 developmental biology[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases030211 gastroenterology & hepatologyFemaleFranceSteatosisViral hepatitisbusiness
researchProduct

Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.

2018

ObjectiveHomozygous alpha1-antitrypsin (AAT) deficiency increases the risk for developing cirrhosis, whereas the relevance of heterozygous carriage remains unclear. Hence, we evaluated the impact of the two most relevant AAT variants (‘Pi*Z’ and ‘Pi*S’), present in up to 10% of Caucasians, on subjects with non-alcoholic fatty liver disease (NAFLD) or alcohol misuse.DesignWe analysed multicentric case–control cohorts consisting of 1184 people with biopsy-proven NAFLD and of 2462 people with chronic alcohol misuse, both cohorts comprising cases with cirrhosis and controls without cirrhosis. Genotyping for the Pi*Z and Pi*S variants was performed.ResultsThe Pi*Z variant presented in 13.8% of p…

0301 basic medicineMalemedicine.medical_specialtyHeterozygoteCirrhosisMedizinSingle-nucleotide polymorphismDiseaseGastroenterologyPolymorphism Single NucleotideRisk Assessment03 medical and health sciences0302 clinical medicineAge DistributionLiver Cirrhosis AlcoholicNon-alcoholic Fatty Liver DiseaseInternal medicineGermanymedicinePiConfidence IntervalsOdds RatioHumansGenetic Predisposition to DiseaseRisk factorSex DistributionGenotypingLiver injurybusiness.industryGenetic Carrier ScreeningIncidenceFatty liverBiopsy NeedleGastroenterologyGenetic Variationmedicine.diseasePrognosisImmunohistochemistry030104 developmental biologyAustriaCase-Control Studiesalpha 1-Antitrypsin030211 gastroenterology & hepatologyFemalebusinessGut
researchProduct

Lysosomal acid lipase deficiency: Expanding differential diagnosis.

2016

The differential diagnoses for metabolic liver diseases may be challenging in clinical settings, which represents a critical issue for disorders such as lysosomal acid lipase deficiency (LAL-D). LAL-D is caused by deficient activity of the LAL enzyme, resulting in the accumulation of cholesteryl esters and triglycerides throughout the body, predominately in the liver, spleen, gastrointestinal tract, and blood vessel walls. LAL-D is a progressive, multi-organ disease with early mortality and significant morbidity characterized by a combination of hepatic dysfunction and dyslipidemia. Evidence suggests LAL-D may be substantially underdiagnosed or misdiagnosed, which is critical given that dis…

0301 basic medicineMalemedicine.medical_specialtyPathologyAdolescentEndocrinology Diabetes and MetabolismDiseaseLysosomal acid lipase deficiencyBiochemistryGastroenterologyDiagnosis Differential03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGeneticsmedicineLysosomal storage diseaseHumansChildMolecular BiologyTriglyceridesNiemann-Pick DiseasesGaucher Diseasebusiness.industryWolman DiseaseInfantEnzyme replacement therapySterol Esterasemedicine.diseaseClinical trial030104 developmental biologyEarly DiagnosisSebelipase alfaDisease Progression030211 gastroenterology & hepatologyFemaleCholesterol EstersDifferential diagnosisbusinessDyslipidemiaMolecular genetics and metabolism
researchProduct

Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet

2016

Aim: The purpose of the present study was to investigate the influence of endogenous glucagon-like peptide-2 (GLP-2) on lipid profile in mice fed a standard diet (STD) or a high-fat diet (HFD). Materials and methods: HFD- and age-matched STD mice were injected once a day with GLP-2 (3-33), a GLP-2 receptor (GLP-2R) antagonist, or vehicle for 4 weeks. Results: HFD mice displayed increased intrahepatic lipid concentration and hepatic steatosis and higher plasma concentrations of cholesterol, LDL, AST, and ALT than STD mice. No difference was observed in lipid fecal elimination. In STD mice, the chronic treatment with GLP-2 (3-33) did not affect any parameter, while in HFD mice, it enhanced pl…

0301 basic medicineMalemedicine.medical_specialtyobesityEndogenyBiologyDiet High-FatliverSettore BIO/09 - Fisiologia03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineInsulin resistanceEndocrinologyMetabolic DiseaseslipidInternal medicineinsulin resistancemedicineGlucagon-Like Peptide 2AnimalsReceptormedicine.diagnostic_testCholesterolSettore BIO/16 - Anatomia Umanadigestive oral and skin physiologyAntagonistGeneral Medicinemedicine.diseaseGlucagon-like peptide-2LipidsPeptide FragmentsMice Inbred C57BL030104 developmental biologyEndocrinologychemistrylipids (amino acids peptides and proteins)030211 gastroenterology & hepatologySteatosisLipid profileGLP-2hormones hormone substitutes and hormone antagonists
researchProduct

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis…

2019

Wong, Grace LH/0000-0002-2863-9389; Wong, Vincent WS/0000-0003-2215-9410; Mangia, A/0000-0002-2600-3555; Brahmania, Mayur/0000-0002-4671-1479; Chan, Henry Lik-Yuen/0000-0002-7790-1611; Brouwer, Willem Pieter/0000-0001-8713-1481; Feld, Jordan/0000-0003-2640-2211; Tanwandee, Tawesak/0000-0001-7634-0843; Jaroszewicz, Jerzy/0000-0003-0139-4753; Chuaypen, Natthaya/0000-0002-5415-510X

0301 basic medicineMicrobiology (medical)AdultMaleHBsAgHepatitis B virusSettore MED/09 - Medicina InternaGenotyping TechniquesGenome-wide association studymedicine.disease_causePeripheral blood mononuclear cellAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicSDG 3 - Good Health and Well-beingPegylated interferonInterferonmedicineHumansGWASchronic hepatitis BgeneticsProspective StudiespeginterferonArticles and CommentariesHepatitis B virusresponsebusiness.industryInterleukinInterferon-alphaMiddle Aged3. Good health030104 developmental biologyInfectious DiseasesHBeAgImmunologyMultivariate Analysis030211 gastroenterology & hepatologyFemaleInterferonsbusinessmedicine.drugGenome-Wide Association StudyClinical Infectious Diseases
researchProduct

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

2020

Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers&rsquo

0301 basic medicineMicrobiology (medical)HBsAgmedicine.medical_specialtyimmunosuppressive therapyHbv markersmedicine.disease_causeMicrobiologyGastroenterologyArticleVirus03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineIn patientlcsh:QH301-705.5Hepatitis B virusbusiness.industryrheumatic patientsvirus diseasesHBV vaccineHBV markersmedicine.diseaseConnective tissue diseasedigestive system diseasesVaccinationTiter030104 developmental biologylcsh:Biology (General)030211 gastroenterology & hepatologybusinessHBV markers; HBV vaccine; immunosuppressive therapy; rheumatic patientsMicroorganisms
researchProduct

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association f…

2018

Abstract Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict …

0301 basic medicineNephrologyDirect-acting antiviral agentmedicine.medical_treatment030232 urology & nephrologyDiseaseHepacivirusurologic and male genital diseasesSeverity of Illness IndexLiver disease0302 clinical medicineRisk FactorsChronic kidney diseasePrevalenceRenal Insufficiency030212 general & internal medicineChronicCooperative BehaviorChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Antiviral Agents; Cooperative Behavior; Expert Testimony; Hepacivirus; Hepatitis C; Humans; Infectious Disease Medicine; Internal Medicine; Italy; Kidney Transplantation; Nephrology; Renal Insufficiency Chronic; Risk Factors; Severity of Illness Index; Societies; Disease ManagementSocieties MedicalKidney transplantationInfectious Disease Medicineeducation.field_of_studyEvidence-Based MedicineGastroenterologyDisease ManagementHepatitis CGeneral MedicineHepatitis CHCV in renal transplantationHCV infectionInfectious DiseasesTreatment OutcomeChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Hepatology; GastroenterologyItalyNephrologyEmergency Medicine030211 gastroenterology & hepatologyHemodialysisHumanMicrobiology (medical)medicine.medical_specialtyConsensus030106 microbiologyPopulationConsensuAntiviral AgentsRisk Assessment03 medical and health sciencesRenal DialysisInternal medicineChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infectionInternal MedicinemedicineHumansRenal Insufficiency ChroniceducationExpert TestimonyAntiviral AgentHepaciviruHepatologybusiness.industryRisk FactorHepatitis C Chronicmedicine.diseaseKidney TransplantationTransplantationDirect-acting antiviral agentsSocietiesbusinessChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Hepacivirus; Hepatitis C; Humans; Italy; Renal Insufficiency ChronicChronic kidney disease Direct-acting antiviral agents HCV in renal transplantation HCV infection NephrologyKidney disease
researchProduct

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

2019

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.

0301 basic medicineOccult HBV infectionHepatitis B virusmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaHbv reactivationMEDLINEHBV reactivationOBImedicine.disease_cause03 medical and health sciences0302 clinical medicineHBV S variantRisk FactorsmedicineHumansHepatitis B AntibodiesIntensive care medicineComputingMilieux_MISCELLANEOUSHepatitis B virusHepatitis B Surface AntigensHepatologyHBV cccDNALiver Neoplasmsvirus diseasesHBV cccDNA; HBV reactivation; HBV S variants; HBV transmission; Hepatocellular carcinoma; OBI; Occult HBV infectionHBV S variantsHepatitis Bmedicine.diseaseOccultdigestive system diseases3. Good healthHBV S variants; HBV cccDNA; HBV reactivation; HBV transmission; Hepatocellular carcinoma; OBI; Occult HBV infection030104 developmental biologyLiverHepatocellular carcinomaDNA Viral030211 gastroenterology & hepatologyHBV transmission[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct